Lina Elfaki: Anticoagulation Medications – A Critical Component of Patient Safety
Lina Elfaki, Senior clinical pharmacist, shared on LinkedIn:
“Anticoagulation Medications: A Critical Component of Patient Safety
Anticoagulation therapy plays a vital role in preventing and managing thromboembolic disorders across medical and surgical settings. From atrial fibrillation to post-operative care, the safe and effective use of anticoagulants requires careful clinical judgment and monitoring.
Key Anticoagulation Medications:
• Heparin & Low-Molecular-Weight Heparins (Enoxaparin)
• Vitamin K Antagonists (Warfarin)
• Direct Oral Anticoagulants (DOACs): Apixaban, Rivaroxaban, Dabigatran, Edoxaban
Clinical Focus Areas:
• Individualized dosing based on renal function and patient risk
• Monitoring for bleeding and thrombotic complications
• Managing drug–drug and drug–food interactions
• Peri-operative anticoagulation planning
• Patient education to ensure adherence and safety
Interdisciplinary collaboration—especially involving clinical pharmacists—enhances therapeutic outcomes and minimizes preventable adverse events.”
Stay updated on Hemostasis Today.
-
Jul 18, 2026, 15:57Ghaya Nasr: Advancing Care Standards and Therapeutic Progress at ISTH 2026
-
Jul 18, 2026, 15:49Heghine Khachatryan: ISTH 2026 – Final Day Highlights
-
Jul 18, 2026, 15:40Marc Carrier: New ISTH 2026 Data May Simplify DVT Evaluation During Pregnancy
-
Jul 18, 2026, 15:38Hermine Sayiyan: Dreams Do Come True – Often When We Least Expect Them
-
Jul 18, 2026, 15:31Alyaa Al-Mughairy: Presenting Real-World Emicizumab Data at the ISTH 2026 Middle East Summit
-
Jul 18, 2026, 15:25Rim Diab: Presenting Protein S Research as a Rebalancing Strategy at ISTH 2026
-
Jul 18, 2026, 15:22Owen McCarty: Honored to Speak at the 1st Mediterranean Platelet Symposium
-
Jul 18, 2026, 15:18Strengthening Regional Learning for Hemophilia and Sickle Cell Disease Care – Novo Nordisk
-
Jul 18, 2026, 14:54Fabien Mselati: Reflecting on 25 Years of Hemophilia Progress